Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD
Status:
Recruiting
Trial end date:
2024-12-12
Target enrollment:
Participant gender:
Summary
This clinical trial aims to evaluate the efficacy and safety of pembrolizumab in the
first-line treatment of advanced NSCLC complicated with COPD and its influence on the course
of COPD, so as to provide prospective clinical evidence for immunotherapy of NSCLC
complicated with COPD in China and to guide clinical application.